Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations

Tue Mar 5, 2013 8:03am EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130305:nGNXUXHIXa

CORAL GABLES, Fla., March 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc.
(Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization
of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is
pleased to announce today the appointment of Bernardino Mosquera, M.D. as Vice President of
Clinical Operations. Dr. Mosquera will be responsible for the operational oversight of Catalyst's
clinical trials and the management of collaborations with clinical service providers such as
clinical research organizations (CROs) and central laboratories.

"With our ongoing Phase III trial of FirdapseTM for the treatment of LEMS, this is an excellent
time to welcome someone of Dr. Mosquera's caliber to our management team," said Steven Miller,
Ph.D., Chief Operating Officer of Catalyst. "Dr. Mosquera's past experience will be an invaluable
addition to our clinical programs, and we look forward to working with him."

For the past three years, Dr. Mosquera has been managing his own clinical research consulting
company. As an independent consultant, he was involved in trials for Alzheimer's, Parkinson's, and
stroke medications for a multinational pharmaceutical company and several biotech companies. Prior
to his independent experience, he spent five years, first at Amgen, then as a dedicated contractor
for Amgen, on a number of phase III trials in the oncology area. Prior to joining Amgen, he was
with Kos Pharmaceuticals up until its acquisition by Abbott where he was involved in all aspects
of clinical trial management for two Phase III trials for a hyperlipidemia treatment. This
experience included CRO selection, site selection, vendor management, creating all study
documents, IRB submissions, trial management, and CRA management.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neurological
diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and
Tourette's disorder. Catalyst's lead candidate, Firdapse for the treatment of LEMS, is currently
undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing
a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat
infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement
disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. A number of factors, including whether any
of the Company's product candidates will ever be approved for commercialization and those factors
described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect the Company. Copies of the Company's filings with the SEC are available from the
SEC, may be found on the Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained herein, which speaks
only as of this date.

CONTACT: For Further Information Contact:
         Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
         
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.